Publication date: Jun 25, 2025
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntingtons Disease. Skyhawk noted that the company hopes it can support the development of lower-cost, large scale therapy for patients with HD around the world. REFERENCES1. Lower dosages, including the 3 mg and 1 mg cohorts, also produced reductions of 41% and 19%, respectively, in treated patients. Despite decades of research, therapeutic progress has been limited, and current treatments are symptomatic. Skyhawk Therapeutics. News Release. Accessed June 24, 2025. https://www. skyhawktx. com/post/skyhawk-therapeutics-announces-first-patient-dosed-in-phase-2-3-falcon-hd-trial-of-sky-0515-for-hunt2.
| Concepts | Keywords |
|---|---|
| Australia | Disease |
| July | Dose |
| Nct06873334 | Falcon |
| Neurologist | Hd |
| Skyhawk | Htt |
| Huntington | |
| Participants | |
| Patient | |
| Phase | |
| Sky | |
| Skyhawk | |
| Splicing | |
| Therapeutics | |
| Treatment | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | spinal muscular atrophy |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | trinucleotide repeat expansion |
| disease | MESH | neurodegenerative disorder |
| pathway | KEGG | Huntington disease |
| disease | MESH | Huntington Disease |
| drug | DRUGBANK | Coenzyme M |
| pathway | REACTOME | Release |
Original Article
(Visited 4 times, 1 visits today)